Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Aug;45(4):783-792.
doi: 10.1111/jcpt.13167. Epub 2020 May 14.

The effect of metformin on lung cancer risk and survival in patients with type 2 diabetes mellitus: A meta-analysis

Kang Xiao  1   2 , Fengxi Liu  1   3 , Juan Liu  1 , Jiwei Xu  1 , Qiuyun Wu  1 , Xiao Li  1   3
Affiliations
Meta-Analysis

The effect of metformin on lung cancer risk and survival in patients with type 2 diabetes mellitus: A meta-analysis

Kang Xiao et al. J Clin Pharm Ther. 2020 Aug.

Abstract

What is known and objective: Metformin has received increasing attention owing to its potential protective effect against cancer. We aimed to summarize evidence regarding the association between metformin and the risk or survival in lung cancer patients with type 2 diabetes.

Methods: We selected observational studies examining the association between exposure to metformin and the risk or survival in lung cancer. Available publications were searched in PubMed, Cochrane Library, ScienceDirect, Wiley and SpringerLink databases. Meta-analysis was performed with hazard ratios (HRs) and 95% confidence intervals (95% CIs) as effect measures for risk or survival in lung cancer.

Results: Eighteen studies (eight on lung cancer risk and ten on lung cancer survival) were included. Metformin treatment was associated with decreased lung cancer incidence (HR 0.78; 95% CI 0.70-0.86) and increased lung cancer survival (HR 0.65; 95% CI 0.55-0.77). In the subgroup analysis by ethnicity, a significant protective effect of metformin use on lung cancer risk was observed among Asian patients (HR 0.66; 95% CI 0.56-0.76), but not in European patients. On the other hand, the protective effect of metformin use on lung cancer survival was observed in both Asian (HR 0.57; 95% CI 0.49-0.66) and non-Asian (HR 0.79; 95% CI 0.71-0.88) patients. In the subgroup analysis by histology, a protective effect of metformin on lung cancer survival was observed in both non-small-cell lung cancer (HR 0.68; 95% CI 0.54-0.84) and small-cell lung cancer (HR 0.52; 95% CI 0.39-0.69). Funnel plot showed that no significant publication bias existed.

Conclusions: Our findings demonstrate that metformin is significantly associated with a decreased risk and increased survival in lung cancer.

Keywords: lung cancer incidence; lung cancer survival; meta-analysis; metformin; type 2 diabetes mellitus.

PubMed Disclaimer

References

REFERENCES

    1. Del Barco S, Vazquez-Martin A, Cufí S, et al. Metformin: multi-faceted protection against cancer. Oncotarget. 2011;2(12):896-917.
    1. Ben Sahra I, Regazzetti C, Robert G, et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Can Res. 2011;71(13):4366-4372.
    1. Alcusky M, Keith SW, Karagiannis T, Rabinowitz C, Louis DZ, Maio V. Metformin exposure and survival in head and neck cancer: a large population-based cohort study. J Clin Pharm Ther. 2019;44(4):588-594.
    1. Shah RR, Stonier PD. Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead. J Clin Pharm Ther. 2019;44(1):6-22.
    1. Gong TT, Wu QJ, Lin B, Ruan SK, Kushima M, Takimoto M. Observational studies on the association between post-diagnostic metformin use and survival in ovarian cancer: a systematic review and meta-analysis. Front Oncol. 2019;9:458.

Publication types

MeSH terms

LinkOut - more resources